Wang Jir-You, Wu Po-Kuei, Chen Paul Chih-Hsueh, Yen Chuen-Chuan, Hung Giun-Yi, Chen Cheng-Fong, Hung Shih-Chieh, Tsai Shih-Fen, Liu Chien-Lin, Chen Tain-Hsiung, Chen Wei-Ming
Department of Orthopaedics, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Orthopaedics, Therapeutical and Research Center of Musculoskeletal Tumor, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
Department of Orthopaedics, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Orthopaedics, Therapeutical and Research Center of Musculoskeletal Tumor, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Surgery and Institute of Clinical Medicine School, National Yang-Ming University, Taipei, Taiwan.
PLoS One. 2014 May 7;9(5):e96571. doi: 10.1371/journal.pone.0096571. eCollection 2014.
Osteosarcoma (OS) patients who suffer manipulation therapy (MT) prior to diagnosis resulted in poor prognosis with increasing metastasis or recurrence rate. The aim of the study is to establish an in vivo model to identify the effects of MT on OS. The enrolled 235 OS patients were followed up in this study. In vivo nude mice model with tibia injection of GFP-labeled human OS cells were randomly allocated into MT(+) that with repeated massage on tumor site twice a week and no treatment as MT(-) group. The five-year survival, metastasis and recurrence rates were recorded in clinical subjects. X-ray plainfilm, micro-PET/CT scan, histopathology, serum metalloproteinase 2 (MMP2), metalloproteinase 9 (MMP9) level and human kinase domain insert receptor (KDR) pattern were assayed in mice model. The results showed that patient with MT decreased 5-year survival and higher recurrence or metastasis rate. Compatible with clinical findings, the decreased body weight (30.5 ± 0.65 g) and an increased tumor volume (8.3 ± 1.18 mm3) in MT(+) mice were observed. The increasing signal intensity over lymph node region of hind limb by micro-PET/CT and the tumor cells were detected in lung and bilateral lymph nodes only in MT(+) group. MMP2 (214 ± 9.8 ng/ml) and MMP9 (25.5 ± 1.81 ng/ml) were higher in MT(+) group than in MT(-) group (165 ± 7.8 ng/ml and 16.9 ± 1.40 ng/ml, individually) as well as KDR expression. Taking clinical observations and in vivo evidence together, MT treatment leads to poor prognosis of primary osteosarcoma; physicians should pay more attention on patients who seek MT before diagnosis.
在诊断前接受手法治疗(MT)的骨肉瘤(OS)患者预后较差,转移或复发率增加。本研究的目的是建立一个体内模型,以确定MT对OS的影响。本研究对纳入的235例OS患者进行了随访。将通过胫骨注射绿色荧光蛋白标记的人OS细胞建立的体内裸鼠模型随机分为MT(+)组,每周对肿瘤部位进行两次重复按摩,未治疗的作为MT(-)组。记录临床受试者的五年生存率、转移率和复发率。对小鼠模型进行X线平片、微型PET/CT扫描、组织病理学、血清金属蛋白酶2(MMP2)、金属蛋白酶9(MMP9)水平和人激酶结构域插入受体(KDR)模式检测。结果显示,接受MT治疗的患者五年生存率降低,复发或转移率更高。与临床结果一致,观察到MT(+)组小鼠体重下降(30.5±0.65 g),肿瘤体积增大(8.3±1.18 mm3)。微型PET/CT显示后肢淋巴结区域信号强度增加,仅在MT(+)组的肺和双侧淋巴结中检测到肿瘤细胞。MT(+)组的MMP2(214±9.8 ng/ml)和MMP9(25.5±1.81 ng/ml)高于MT(-)组(分别为165±7.8 ng/ml和16.9±1.40 ng/ml)以及KDR表达。综合临床观察和体内证据,MT治疗导致原发性骨肉瘤预后不良;医生应更加关注在诊断前寻求MT治疗的患者。